Herein, we demonstrated that the expression profiles of AIM and PSA are inversely correlated in patients with PCa, and that concomitant aberrant expression of PSA with significantly suppressed AIM expression characterizes advanced stage prostate cancer, regardless of mutation status (Figure 1 and Figure 2). This evidence concerns the gene KLK3 and prostate carcinoma.